Symphogen's ITP therapy clears Phase II
This article was originally published in Scrip
Executive Summary
The Danish biotech company Symphogen's rozrolimupab (SYM001) may be a useful alternative to plasma-derived products in the treatment of primary immune thrombocytopenia purpura (ITP), say researchers following a Phase II trial published in Blood.